This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
ShunzymeX leverages a proprietary protease to streamline purification
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
